Sionna Therapeutics Inc
SION
Company Profile
Business description
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which Heads to insufficient CFTR function.
Contact
21 Hickory Drive
Suite 500
WalthamMA02451
USAT: +1 617 819-2020
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
stocks
Our view of the supermarkets after earnings
Are the shares of two of Australia’s best known brands attractive?
stocks
Has uncertainty created an opportunity in Jack Daniel's owner?
Investors seem to be questioning long-term demand trends in alcohol. This may have sent the valuation of Wide Moat spirits company Brown Forman down too far.
stocks
Nvidia earnings: Despite DeepSeek news, no signs of waning near-term chip demand
We’re maintaining our fair value estimate after another strong quarter.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,403.90 | 102.20 | -1.20% |
| CAC 40 | 8,111.63 | 9.11 | 0.11% |
| DAX 40 | 22,551.43 | 0.54 | 0.00% |
| Dow JONES (US) | 43,419.56 | 180.06 | 0.42% |
| FTSE 100 | 8,809.74 | 53.53 | 0.61% |
| HKSE | 22,941.32 | 776.97 | -3.28% |
| NASDAQ | 18,608.92 | 64.50 | 0.35% |
| Nikkei 225 | 37,155.50 | 1,100.67 | -2.88% |
| NZX 50 Index | 12,601.42 | 60.55 | 0.48% |
| S&P 500 | 5,880.83 | 19.26 | 0.33% |
| S&P/ASX 200 | 8,172.40 | 95.80 | -1.16% |
| SSE Composite Index | 3,320.90 | 67.17 | -1.98% |